KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Long-Term Deferred Tax (2021 - 2025)

Historic Long-Term Deferred Tax for Halozyme Therapeutics (HALO) over the last 6 years, with Q2 2025 value amounting to $20.2 million.

  • Halozyme Therapeutics' Long-Term Deferred Tax changed N/A to $20.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $20.2 million, marking a year-over-year change of. This contributed to the annual value of $3.9 million for FY2024, which is 1210.67% down from last year.
  • Halozyme Therapeutics' Long-Term Deferred Tax amounted to $20.2 million in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Long-Term Deferred Tax registered a high of $155.4 million during Q4 2021, and its lowest value of $616000.0 during Q1 2024.
  • Moreover, its 5-year median value for Long-Term Deferred Tax was $22.1 million (2023), whereas its average is $49.3 million.
  • Its Long-Term Deferred Tax has fluctuated over the past 5 years, first tumbled by 9827.37% in 2024, then soared by 74253.25% in 2025.
  • Halozyme Therapeutics' Long-Term Deferred Tax (Quarter) stood at $155.4 million in 2021, then plummeted by 71.42% to $44.4 million in 2022, then plummeted by 90.13% to $4.4 million in 2023, then fell by 12.11% to $3.9 million in 2024, then skyrocketed by 424.2% to $20.2 million in 2025.
  • Its Long-Term Deferred Tax stands at $20.2 million for Q2 2025, versus $5.2 million for Q1 2025 and $3.9 million for Q4 2024.